The biopharmaceutical industry was dealt a blow on June 20 when the US Supreme Court backed the use of the so-called broadest reasonable interpretation (BRI) by the US Patent & Trademark Office Patent Trial and Appeal Board (PTAB) for conducting inter partes reviews (IPRs) – trial proceedings created under the America Invents Act (AIA) in 2011 to be a faster and more affordable alternative to litigation for challenging patents.
In upholding an earlier ruling by the US Court of Appeals for the Federal Circuit in the case, known as...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

